» Articles » PMID: 28656132

Cost-effectiveness of Antibiotics for COPD Management: Observational Analysis Using CPRD Data

Overview
Journal ERJ Open Res
Specialty Pulmonary Medicine
Date 2017 Jun 29
PMID 28656132
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

It is often difficult to determine the cause of chronic obstructive pulmonary disease (COPD) exacerbations, and antibiotics are frequently prescribed. This study conducted an observational cost-effectiveness analysis of prescribing antibiotics for exacerbations of COPD based on routinely collected data from patient electronic health records. A cohort of 45 375 patients aged 40 years or more who attended their general practice for a COPD exacerbation during 2000-2013 was identified from the Clinical Practice Research Datalink. Two groups were formed ("immediate antibiotics" or "no antibiotics") based on whether antibiotics were prescribed during the index general practice (GP) consultation, with data analysed according to subsequent healthcare resource use. A cost-effectiveness analysis was undertaken from the perspective of the UK National Health Service, using a time horizon of 4 weeks in the base case. The use of antibiotics for COPD exacerbations resulted in cost savings and an improvement in all outcomes analysed; GP visits, hospitalisations, community respiratory team referrals, all referrals, infections and subsequent antibiotics prescriptions were lower for the antibiotics group. Hence, the use of antibiotics was dominant over no antibiotics. The economic analysis suggests that use of antibiotics for COPD exacerbations is a cost-effective alternative to not prescribing antibiotics for patients who present to their GP, and remains cost-effective when longer time horizons of 3 months and 12 months are considered. It would be useful for a definitive trial to be undertaken in this area to determine the cost-effectiveness of antibiotics for COPD exacerbations.

Citing Articles

Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review.

Pham H, Pham K, Ha G, Pham T, Nguyen H, Nguyen T Tuberc Respir Dis (Seoul). 2024; 87(3):234-251.

PMID: 38361331 PMC: 11222094. DOI: 10.4046/trd.2023.0100.


Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis.

Lu Z, Xiong X, Lee T, Wu J, Yuan J, Jiang B Front Pharmacol. 2021; 12:700012.

PMID: 34737696 PMC: 8562301. DOI: 10.3389/fphar.2021.700012.


[Current microbiological aspects of community respiratory infection beyond COVID-19].

Canton R Rev Esp Quimioter. 2021; 34(2):81-92.

PMID: 33749214 PMC: 8019468. DOI: 10.37201/req/049.2021.


Economic Evaluations Informed Exclusively by Real World Data: A Systematic Review.

Parody-Rua E, Rubio-Valera M, Guevara-Cuellar C, Gomez-Lumbreras A, Casajuana-Closas M, Carbonell-Duacastella C Int J Environ Res Public Health. 2020; 17(4).

PMID: 32059593 PMC: 7068655. DOI: 10.3390/ijerph17041171.


Opportunities to reduce antibiotic prescribing for patients with COPD in primary care: a cohort study using electronic health records from the Clinical Practice Research Datalink (CPRD).

Rockenschaub P, Jhass A, Freemantle N, Aryee A, Rafiq M, Hayward A J Antimicrob Chemother. 2019; 75(1):243-251.

PMID: 31598669 PMC: 6910166. DOI: 10.1093/jac/dkz411.


References
1.
Seemungal T, Sykes A . Recent advances in exacerbations of COPD. Thorax. 2008; 63(10):850-2. DOI: 10.1136/thx.2008.099127. View

2.
Vollenweider D, Jarrett H, Steurer-Stey C, Garcia-Aymerich J, Puhan M . Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012; 12:CD010257. DOI: 10.1002/14651858.CD010257. View

3.
van Staa T, Dyson L, McCann G, Padmanabhan S, Belatri R, Goldacre B . The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. Health Technol Assess. 2014; 18(43):1-146. PMC: 4781625. DOI: 10.3310/hta18430. View